VIC-1911 is under clinical development by VITRAC Therapeutics and currently in Phase II for Graft Versus Host Disease (GVHD). According to GlobalData, Phase II drugs for Graft Versus Host Disease (GVHD) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VIC-1911’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VIC-1911 was under development for the treatment of advanced solid tumor including breast cancer, ovarian cancer, small-cell lung cancer, pancreatic cancer, colon cancer, non-small cell lung cancer and fallopian tube cancer. It is a small molecule administered orally. It acts as selective aurora A inhibitor. Aurora A is a serine/ threonine kinase that plays a critical role in regulating multiple mitosis processes.
The drug candidate is under development for the prevention of graft-versus-host disease (GVHD).
For a complete picture of VIC-1911’s drug-specific PTSR and LoA scores, buy the report here.